Sanford (Sandy) Zweifach President & Chief Executive Officer
Sanford Zweifach is senior executive with over 25 years’ experience in the life sciences industry. He has an extensive background in corporate partnering, business development, operations, private and public investing, and capital raising. He is the Founder and Chief Executive Officer of Nuvelution Pharma, Inc. Previously, Mr. Zweifach served as CEO of Ascendancy Healthcare, Inc., which he also founded. He has also been a Partner at Reedland Capital Partners, a boutique investment bank, where he headed its life sciences M&A and advisory efforts. Prior to this, he was CEO of Pathways Diagnostics, a biomarker development company. Mr. Zweifach was a Managing Director/CFO of Bay City Capital, a venture capital/merchant banking firm, specializing in the biotech and the life science industry, where he was President of the firm’s M&A and financing division and was also responsible for oversight of the firm’s finance department. Prior to this, he was President and CFO of Epoch Biosciences, which was acquired by Nanogen in 2004. Currently, he is Chairman of Lyric Pharmaceuticals Inc., Chairman of IMIDomics, S.L., a Director of Realm Therapeutics, Inc., and a Director of Compugen Ltd. Earlier in his career, Mr. Zweifach was a Certified Public Accountant for Coopers & Lybrand and held various investment banking positions focusing on biotech. He received his BA in Biology from UC San Diego and an MS in Human Physiology from UC Davis.
Barry Gertz, MD, PhD Chief Physician Scientist
Barry Gertz, MD, PhD, is Venture Partner at Clarus Ventures and Chief Medical Advisor for Relay Pharmaceuticals, Inc., a Clarus-backed development company. Prior to joining Clarus, Dr. Gertz was Senior Vice President of Global Clinical Development at Merck, where he was responsible for overseeing all aspects of Merck's clinical research from exploratory clinical pharmacology to global Phase 3 trials and life cycle management. He was instrumental in the development and approval of more than 25 new drugs and vaccines, including six new approvals in 2014, as well as the blockbuster products Fosamax® and Januvia®. Dr. Gertz also has co-authored over a hundred scientific publications and articles. Dr. Gertz received an MD, PhD, as well as BA, from the University of Pennsylvania. He trained in internal medicine at the Hospital of the University of Pennsylvania and held fellowship and faculty positions at University of California San Francisco.
James Cornwall, PhD Chief Business Officer
James Cornwall, PhD, brings more than 25 years of clinical development, operational and strategy experience across preclinical, exploratory and late phase in large pharma, biotech and CRO, including strategic portfolio management. Dr. Cornwall most recently served as Vice President of Corporate Development for Quintiles, the world’s largest pharmaceutical services provider. During his tenure at Quintiles, he oversaw the development of strategic partnerships with biopharmaceutical companies and financial institutions across the US, EU, and Asia Pacific region. He also worked for Quintiles private equity investment groups PharmaBio Development and NovaQuest, where he led and managed multiple transactions with biopharma companies. Dr. Cornwall gained a BSc in Pharmacology and a PhD in Neuropharmacology from the University Of Bristol, and completed postgraduate training in Executive Leadership at the University of North Carolina Kenan Flagler Business School.
Joe Poirier Chief Financial Officer
Joe Poirier joined the Nuvelution team in January 2016, bringing more than 20 years' experience in the Medical Device and Life Science industries, in the disciplines of Finance, Accounting, Business Development and Administration. Most recently, he served as Chief Financial Officer with SFJ Pharmaceuticals, a company focused on pharmaceutical development partnering and strategic funding. Prior to that, Mr. Poirier held a variety of financial leadership positions within the Corporate Finance, Corporate Tax and Global Operations groups at Boston Scientific, one of the world’s largest developers, manufacturers and marketers of medical devices. Mr. Poirier holds an MBA from Providence College and a BS Degree in Finance from Bryant University in Smithfield Rhode Island.